Skip to main content

Zealand Pharma major shareholder announcement: Polar Capital

Company announcement – No. 47 / 2022

Zealand Pharma major shareholder announcement: Polar Capital

Copenhagen, Denmark and Boston, MA, 11 October 2022Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 11 October 2022 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

As of 10 October 2022, Polar Capital LLP holds nominally 5,930,317 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 11.51% of the total share capital and total voting rights in Zealand Pharma A/S.

Please see further details in the attached notification form.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com

 

David Rosen (U.S. Media)
Argot Partners
Email: media@zealandpharma.com
        

 

Attachment


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.